Doron Levy: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Next edit →
Content deleted Content added
VisualWikitext
←Created page with '{{Infobox academic | name = Doron Levy | image = | birth_date = | birth_place = | nationality = | occupation = Mathematician, scientist, magician, and academic | title = | awards = | website = | education = B.Sc. in Mathematics and Physics<br>M.Sc. in Applied Mathematics<br>Ph.D. in Applied Mathematics | alma_mater = Tel Av...'
(No difference)

Revision as of 05:19, 11 August 2023

Doron Levy
Occupation(s)Mathematician, scientist, magician, and academic
Academic background
EducationB.Sc. in Mathematics and Physics
M.Sc. in Applied Mathematics
Ph.D. in Applied Mathematics
Alma materTel Aviv University
ThesisTopics in Approximate Methods for Non-Linear Partial Differential Equations (1997)
Doctoral advisorEitan Tadmor
Academic work
InstitutionsÉcole normale supérieure (Paris)
Paris 6 University (Sorbonne University)
University of California, Berkeley
Lawrence Berkeley National Laboratory
Stanford University
University of Maryland, College Park

Doron Levy is a mathematician, scientist, magician, and academic. He is a Professor and Chair at the Department of Mathematics at the University of Maryland, College Park.[1] He is also the Director of the Brin Mathematics Research Center.[2]

Levy's research encompasses the field of numerical analysis, applied nonlinear PDEs, and biology and medical applications, particularly focusing on analyzing cancer dynamics, immunology, and cell motility. He has written more than 100 peer-reviewed articles. He is the recipient of the National Science Foundation Career Award.[3]

Levy is a Fellow of the John Simon Guggenheim Memorial Foundation[4] He is the Editor-in-Chief of ImmunoInformatics.[1]

Education

Levy earned his Baccalaureate degree in Mathematics and Physics in 1991 and completed a Masters in Applied Mathematics in 1994 from Tel Aviv University. His Master's thesis was titled "From Semi-Discrete to Fully-Discrete: The Stability of Runge-Kutta Schemes by the Energy Method".[5] In 1997, he received a Ph.D. in Applied Mathematics under the guidance of Eitan Tadmor, with a thesis on "Topics in Approximate Methods for Non-Linear Partial Differential Equations." Afterward, he held several post-doctorate fellowships at Laboratoire d'Analyse Numerique (University of Paris 6), École normale supérieure (Paris), University of California, Berkeley, and the Lawrence Berkeley National Laboratory.[6]

Career

Following his post-doctoral fellowship at Berkeley in 2000, Levy joined the Department of Mathematics at Stanford University as an Assistant Professor. In 2007, he was appointed as Associate Professor of Mathematics and a member of the Center for Scientific Computation and Mathematical Modeling (CSCAMM) at the University of Maryland, College Park. In 2014, he became a Pauli Fellow at the Wolfgang Pauli Institute of the University of Vienna in Austria.[7] Since 2011, he has been a Professor at the Department of Mathematics & Center for Scientific Computation and Mathematical Modeling of the University of Maryland, College Park.[8]

As of 2020, Levy has been a Chair at the Department of Mathematics & the Director of the Center for Scientific Computation and Mathematical Modeling (CSCAMM) of the University of Maryland, College Park.[1]

Research

Levy's research is focused on mathematical equations and biomedical applications of mathematics with a particular interest in cancer dynamics, drug resistance, drug delivery, immunology, imaging, and cell motility.[6]

Numerical analysis

During his early research career, Levy worked on developing and analyzing high-order numerical methods for approximating solutions to hyperbolic conservation law and related equations. He developed novel methods for approximating solutions to nonlinear partial differential equations including Euler equations, Navier-Stokes equations, Hamilton-Jacobi equations, nonlinear dispersive equations. Some of the approximation methods he developed used Weighted Essentially Non-Oscillatory (WENO) schemes.[9] He developed a third-order central scheme for approximating solutions of multidimensional hyperbolic conservation laws[10] and 2D conservation laws using compact central WENO reconstructions.[11] In a series of works with Steve Bryson, he proposed new high-order central schemes[12] for approximating solutions of multidimensional Hamilton-Jacobi equations.[13][14]

Cancer dynamics and the immune system

Levy contributed to cancer dynamics by formulating a set of computational and mathematical tools designed for specific types of cancer.[15] He discussed the need for mathematical models to understand the complexity of breast and ovarian cancers[16] and proposed a model to explain the failure of transvaginal ultrasound-based screening in detecting low-volume high-grade serous ovarian cancer.[17] In a collaborative study, he investigated the effects of regulatory T cell switching the immune response and identified a biologically testable range for the switching parameter.[18] Furthermore, he presented mathematical models for studying cancer cell growth dynamics[19] in response to antimitotic drug treatment in vitro,[20] to understand the immunogenic effects of LSD1 inhibition on tumor growth and T cell dynamics,[21] and for the interaction between immune response and cancer cells in chronic myelogenous leukemia and analyzes the stability of steady states.[22]

Levy analyzed cancer's immune response mechanisms, particularly in chronic myeloid leukemia, providing insights into the role of the immune response and drug therapy in controlling the disease.[23] He also demonstrated that the autologous immune system may play a role in the BCR-ABL transcript variations observed in chronic phase chronic myelogenous leukemia patients on imatinib therapy.[24] Considering the problem of drug resistance in cancer[25] he suggested a simple compartmental system of ordinary differential equations to model it[26] and stated that drug resistance depends on the turnover rate of cancer cells.[27] Additionally, he extended a model of drug resistance in solid tumors to explore the dynamics of resistance levels and the emergence of heterogeneous tumors in response to chemotherapy.[28][29] Conducting a study on cervical cancer, he investigated the efficacy of combination immunotherapy using engineered T cells and IL-2.[30] Moreover, he assessed the influence of cell density,[31] intratumoral heterogeneity,[32] and mutations in multidrug resistance,[33] considering the continuum model as the most suitable approach for modeling resistance heterogeneity in metastasis.[34][35] In collaboration with Heyrim Cho, he also investigated the impact of competition between cancer cells and healthy cells on optimal drug delivery and indicated that in scenarios with moderate competition, combination therapies are more effective, whereas in highly competitive situations, targeted drugs prove to be more effective.[36]

Awards and honors

Selected articles

  • Levy, D., & Tadmor, E. (1998). From semidiscrete to fully discrete: Stability of Runge--Kutta schemes by the energy method. SIAM review, 40(1), 40-73.
  • Kim, P. S., Lee, P. P., & Levy, D. (2008). Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS computational biology, 4(6), e1000095.
  • Tomasetti, C., & Levy, D. (2010). Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proceedings of the National Academy of Sciences, 107(39), 16766-16771.
  • Lavi, O., Greene, J. M., Levy, D., & Gottesman, M. M. (2013). The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer research, 73(24), 7168-7175.
  • Cho, H., & Levy, D. (2018). Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth. Journal of theoretical biology, 436, 120-134.

References

  1. ^ a b c "Dr. Doron Levy".
  2. ^ "Director".
  3. ^ a b "NSF Award Search: Award # 0820817 - CAREER: Partial Differential Equation-based Image Processing with Applications to Radiation Oncology".
  4. ^ a b "Doron Levy - John Simon Guggenheim Memorial Foundation".
  5. ^ "From Semidiscrete to Fully Discrete: Stability of Runge--Kutta Schemes by The Energy Method - SIAM Review".
  6. ^ a b "Dr. Doron Levy, PhD - Editorial Board - ImmunoInformatics - Journal - Elsevier".
  7. ^ "athematical models in Biology and Medicine (2017/2018)".
  8. ^ "Department of Mathematics - Levy, Doron".
  9. ^ "On the behavior of the total variation in CWENO methods for conservation laws".
  10. ^ "Compact Central WENO Schemes for Multidimensional Conservation Laws".
  11. ^ "A third order central WENO scheme for 2D conservation laws".
  12. ^ "High-order central WENO schemes for 1D Hamilton-Jacobi equations".
  13. ^ "High-Order Central WENO Schemes for Multidimensional Hamilton-Jacobi Equations".
  14. ^ "Central WENO Schemes for Hamilton–Jacobi Equations on Triangular Meshes".
  15. ^ "New Computational Tools for Modeling Chronic Myelogenous Leukemia".
  16. ^ "Mathematical models of breast and ovarian cancers".
  17. ^ "Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection".
  18. ^ "Functional Switching and Stability of Regulatory T Cells".
  19. ^ "Modeling intrinsic heterogeneity and growth of cancer cells".
  20. ^ "Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment".
  21. ^ "Modeling LSD1-Mediated Tumor Stagnation".
  22. ^ "Stability Analysis of a Model of Interaction Between the Immune System and Cancer Cells in Chronic Myelogenous Leukemia".
  23. ^ "The role of the autologous immune response in chronic myelogenous leukemia".
  24. ^ "Full article: BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system".
  25. ^ "The dynamics of drug resistance: A mathematical perspective".
  26. ^ "An elementary approach to modeling drug resistance in cancer".
  27. ^ "Drug Resistance always Depends on the Turnover Rate".
  28. ^ "Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy".
  29. ^ "Modeling the Transfer of Drug Resistance in Solid Tumors".
  30. ^ "Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer - ScienceDirect".
  31. ^ "Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response".
  32. ^ "The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance".
  33. ^ "The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors".
  34. ^ "Simplifying the complexity of resistance heterogeneity in metastasis: Trends in Molecular Medicine".
  35. ^ "Modeling continuous levels of resistance to multidrug therapy in cancer".
  36. ^ "The impact of competition between cancer cells and healthy cells on optimal drug delivery".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Doron_Levy&oldid=1169772689"